Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.046
Journals
Bioengineering
Special Issues
Recent Advances in Skin Repair and Regeneration
share announcement

Special Issue "Recent Advances in Skin Repair and Regeneration"

A special issue of Bioengineering (ISSN 2306-5354). This special issue belongs to the section "Regenerative Engineering".

Deadline for manuscript submissions: 31 December 2023 | Viewed by 1938

Special Issue Editors

Dr. Anna Michopoulou

E-Mail Website
Guest Editor
Laboratory of Biological Chemistry, Medical School, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
Interests: cell culture; western blot analysis; PCR; cell signaling; molecular cell biology; SDS-PAGE; RNA isolation; cell line culture; immunohistochemistry; immunofluorescence
Dr. Patricia Rousselle

E-Mail Website
Guest Editor
Laboratoire de Biologie Tissulaire et Ingénierie Thérapeutique, UMR 5305, CNRS-Université Lyon 1, SFR BioSciences Gerland-Lyon Sud, 7 Passage du Vercors, 69367 Lyon, France
Interests: cell adhesion; cell migration; cellular imaging; wound healing; epidermal regeneration; keratinocyte; extracellular matrix; basement membrane; integrin; syndecan

Special Issue Information

Dear Colleagues,

Defects in wound healing after injuries or diseases related to impaired skin tissue repair, such as diabetes, aging, cancer, etc., constitute a major public health concern. Despite the progress in the field of skin biology and regeneration, we still need to better understand the mechanisms that regulate skin tissue repair to provide more adequate therapeutic options. Currently, there is huge demand for the development of reconstructed skin equivalents to serve either as grafts to restore skin barrier function after injury and to facilitate wound healing or as in vitro skin models for the study of skin mechanobiology, dysfunctional skin mechanobiology leading to disease and abnormal wound healing, toxicity and pharmaco-cosmetics testing.

The aim of this Special Issue is to collect important contributions and potential breakthroughs in regenerative research and technologies for the development of in vitro skin models, skin disease simulation and the validation of pharmaceuticals/cosmetics.

Potential topics include, but are not limited to:

  • Stem cells
  • Tissue engineering
  • Organ-on-a-chip
  • 3D printing
  • Biomaterials
  • Mechanobiology

Dr. Anna Michopoulou
Dr. Patricia Rousselle
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Bioengineering is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • skin model
  • disease simulation
  • biomaterials
  • skin substitutes

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

get_app
Article
Novel, Blended Polymeric Microspheres for the Controlled Release of Methotrexate: Characterization and In Vivo Antifibrotic Studies
by
Layla Nabai
,
Aziz Ghahary
and
John Jackson
Bioengineering 2023, 10(3), 298; https://doi.org/10.3390/bioengineering10030298 - 27 Feb 2023
Viewed by 666
Abstract
Low dose methotrexate (MTX) is known to effectively decrease type I collagen production in dermal fibroblasts, while increasing the matrix metalloproteinase-1 (MMP-1) production in vitro. For in vivo use as an antifibrotic agent on wounds, a linear and extended controlled release formulation of [...] Read more.
Low dose methotrexate (MTX) is known to effectively decrease type I collagen production in dermal fibroblasts, while increasing the matrix metalloproteinase-1 (MMP-1) production in vitro. For in vivo use as an antifibrotic agent on wounds, a linear and extended controlled release formulation of MTX is required. The objective of this study was to optimize the fabrication of MTX-loaded polymeric microspheres with such properties, and to test the efficacy for the prevention of fibrosis in vivo. Poly lactic-co-glycolic acid (PLGA), Poly (L-lactic acid) (PLLA) and the diblock copolymer, methoxypolyethylene glycol-block-poly (D, L-lactide) (MePEG-b-PDLLA), were used to fabricate microspheres, which were then characterized in terms of size, drug encapsulation efficiency, and in vitro release profiles. The optimized formulation (PLGA with diblock copolymer) showed high drug encapsulation efficiency (>80%), low burst release (~10%) and a gradual release of MTX. The amphipathic diblock copolymer is known to render the microsphere surface more biocompatible. In vivo, these microspheres were effective in reducing fibrotic tissue which was confirmed by quantitative measurement of type I collagen and α-smooth muscle actin expression, demonstrating that MTX can be efficiently encapsulated in PLGA microspheres to provide a delayed, gradual release in wound beds to reduce fibrosis in vivo. Full article
(This article belongs to the Special Issue Recent Advances in Skin Repair and Regeneration)
►▼ Show Figures

Figure 1

Review

Jump to: Research

get_app
Review
Stem Cell Therapies for Epidermolysis Bullosa Treatment
by
Argyrw Niti
,
Georgios Koliakos
and
Anna Michopoulou
Bioengineering 2023, 10(4), 422; https://doi.org/10.3390/bioengineering10040422 - 27 Mar 2023
Viewed by 853
Abstract
Epidermolysis bullosa (EB) includes a group of rare skin diseases characterized by skin fragility with bullous formation in the skin, in response to minor mechanical injury, as well as varying degrees of involvement of the mucous membranes of the internal organs. EB is [...] Read more.
Epidermolysis bullosa (EB) includes a group of rare skin diseases characterized by skin fragility with bullous formation in the skin, in response to minor mechanical injury, as well as varying degrees of involvement of the mucous membranes of the internal organs. EB is classified into simplex, junctional, dystrophic and mixed. The impact of the disease on patients is both physical and psychological, with the result that their quality of life is constantly affected. Unfortunately, there are still no approved treatments available to confront the disease, and treatment focuses on improving the symptoms with topical treatments to avoid complications and other infections. Stem cells are undifferentiated cells capable of producing, maintaining and replacing terminally differentiated cells and tissues. Stem cells can be isolated from embryonic or adult tissues, including skin, but are also produced by genetic reprogramming of differentiated cells. Preclinical and clinical research has recently greatly improved stem cell therapy, making it a promising treatment option for various diseases in which current medical treatments fail to cure, prevent progression, or alleviate symptoms. So far, stem cells from different sources, mainly hematopoietic and mesenchymal, autologous or heterologous have been used for the treatment of the most severe forms of the disease each one of them with some beneficial effects. However, the mechanisms through which stem cells exert their beneficial role are still unknown or incompletely understood and most importantly further research is required to evaluate the effectiveness and safety of these treatments. The transplantation of skin grafts to patients produced by gene-corrected autologous epidermal stem cells has been proved to be rather successful for the treatment of skin lesions in the long term in a limited number of patients. Nevertheless, these treatments do not address the internal epithelia-related complications manifested in patients with more severe forms. Full article
(This article belongs to the Special Issue Recent Advances in Skin Repair and Regeneration)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop